IDIMO, an acronym for ‘Investigation into New Advanced Medical Devices for Enhanced Control and Monitoring of Immune Response and Infections’, is a leading collaborative project in the research and development of innovative medical devices to strengthen the control and monitoring of immune response and associated infections. Under the leadership of I+MEDS. COOP, this ambitious project brings together a consortium of renowned companies and technology centres in the biomedical field in the Basque Country.
The medical device sector is constantly evolving, especially in a demographic environment where the European population is ageing. In response to this trend, the IDIMO consortium has set out to address the current challenges associated with implantable biomedical devices, such as poor integration, infections and adverse foreign body response. These complications represent a significant challenge as they represent an estimated annual cost to European healthcare systems of 9.5 billion euros, which the IDIMO project aims to address with innovative solutions.
The IDIMO project stands out for its multidisciplinary approach, involving leading companies in biomaterials, medical device manufacturing, diagnostics and regulation. Under the leadership and coordination of the cooperative i+Med S.COOP., companies such as AJL OPHTHALMIC S.A., ASPARIA GLYCOMICS S.L., CREATECH MEDICAL, S.L., IMG Pharma Biotech S.L., INNOVATIVE TECHNOLOGIES IN BIOLOGICAL SYSTEMS S.L., and Tecnalia Certificación, together with technology centres such as TECNALIA, CIC BIOMAGUNE, GAIKER, CIDETEC and UPV/EHU, have joined forces to promote research and development in the field of health.
The IDIMO consortium will focus on four key therapeutic areas: traumatology, ophthalmology, odontology and urology, which represent a high demand in the market and cover prevalent pathologies associated with ageing. With a budget of 3.45 million euros and a duration of 33 months, the project aims to research and develop new immunomodulatory biomaterials and diagnostic systems to improve the safety, durability and personalisation of advanced medical devices. The project has been funded by the Basque Government with 1.61 million euros as part of the Hazitek 2023 call for strategic projects.
Dr. Virginia Sáez-Martínez i+Med, leader of the IDIMO consortium, expressed her enthusiasm for the potential impact of this project: ‘IDIMO represents a unique opportunity to advance precision medicine and improve the quality of life of patients. We are committed to developing innovative solutions that address today’s healthcare challenges.
With a vision focused on scientific excellence and interdisciplinary collaboration, the IDIMO consortium is poised to set a significant milestone in the field of medical devices and contribute to the development of a competitive fabric of Basque companies with the capacity to develop proprietary technologies and generate added value in the biomedical sector.
